Stem definition | Drug id | CAS RN |
---|---|---|
diagnostic agents, gadolinium derivatives | 4494 | 131410-48-5 |
Molecule | Description |
---|---|
Synonyms:
|
for intravenous administration with MRI in adult patients for contrast enhancement of CNS lesions
|
None
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 0.20 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.79 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.46 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 8, 1993 | FDA | GE HEALTHCARE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nephrogenic systemic fibrosis | 2174.70 | 52.95 | 346 | 2608 | 3976 | 50598194 |
Skin hypertrophy | 402.61 | 52.95 | 79 | 2875 | 3016 | 50599154 |
Skin induration | 401.28 | 52.95 | 78 | 2876 | 2833 | 50599337 |
Skin tightness | 305.79 | 52.95 | 65 | 2889 | 3698 | 50598472 |
Fibrosis | 195.26 | 52.95 | 45 | 2909 | 3702 | 50598468 |
Skin fibrosis | 194.45 | 52.95 | 35 | 2919 | 824 | 50601346 |
Skin hyperpigmentation | 150.37 | 52.95 | 39 | 2915 | 5237 | 50596933 |
Joint range of motion decreased | 147.07 | 52.95 | 51 | 2903 | 18461 | 50583709 |
Joint contracture | 108.14 | 52.95 | 24 | 2930 | 1660 | 50600510 |
Scar | 103.32 | 52.95 | 35 | 2919 | 11783 | 50590387 |
Emotional distress | 92.09 | 52.95 | 41 | 2913 | 28622 | 50573548 |
Skin discolouration | 89.94 | 52.95 | 42 | 2912 | 32715 | 50569455 |
Anhedonia | 78.51 | 52.95 | 27 | 2927 | 9497 | 50592673 |
Peau d'orange | 75.03 | 52.95 | 12 | 2942 | 134 | 50602036 |
Joint stiffness | 74.44 | 52.95 | 36 | 2918 | 30272 | 50571898 |
Mobility decreased | 73.59 | 52.95 | 50 | 2904 | 79898 | 50522272 |
Oedema peripheral | 69.73 | 52.95 | 64 | 2890 | 157897 | 50444273 |
Erythema | 67.90 | 52.95 | 61 | 2893 | 146353 | 50455817 |
Skin plaque | 64.29 | 52.95 | 21 | 2933 | 6307 | 50595863 |
Deformity | 63.46 | 52.95 | 22 | 2932 | 7918 | 50594252 |
Pain | 62.03 | 52.95 | 116 | 2838 | 578787 | 50023383 |
Muscle contracture | 60.19 | 52.95 | 14 | 2940 | 1193 | 50600977 |
Extremity contracture | 59.72 | 52.95 | 14 | 2940 | 1234 | 50600936 |
Magnetic resonance imaging head abnormal | 54.81 | 52.95 | 14 | 2940 | 1763 | 50600407 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nephrogenic systemic fibrosis | 2272.46 | 49.28 | 386 | 2768 | 3556 | 29567817 |
Skin hypertrophy | 374.99 | 49.28 | 79 | 3075 | 2324 | 29569049 |
Skin tightness | 355.38 | 49.28 | 73 | 3081 | 1891 | 29569482 |
Skin induration | 352.12 | 49.28 | 73 | 3081 | 1981 | 29569392 |
Joint range of motion decreased | 240.72 | 49.28 | 66 | 3088 | 5988 | 29565385 |
Joint contracture | 234.30 | 49.28 | 51 | 3103 | 1749 | 29569624 |
Skin fibrosis | 215.08 | 49.28 | 43 | 3111 | 964 | 29570409 |
Fibrosis | 178.61 | 49.28 | 43 | 3111 | 2316 | 29569057 |
Scar | 165.07 | 49.28 | 48 | 3106 | 5371 | 29566002 |
Extremity contracture | 131.26 | 49.28 | 27 | 3127 | 699 | 29570674 |
Deformity | 128.05 | 49.28 | 30 | 3124 | 1434 | 29569939 |
Emotional distress | 124.27 | 49.28 | 49 | 3105 | 13846 | 29557527 |
Mobility decreased | 122.08 | 49.28 | 58 | 3096 | 25722 | 29545651 |
Joint stiffness | 112.10 | 49.28 | 41 | 3113 | 9432 | 29561941 |
Anhedonia | 103.48 | 49.28 | 36 | 3118 | 7164 | 29564209 |
Pain | 87.56 | 49.28 | 99 | 3055 | 171333 | 29400040 |
Oedema peripheral | 84.27 | 49.28 | 77 | 3077 | 103480 | 29467893 |
Injury | 81.47 | 49.28 | 40 | 3114 | 19006 | 29552367 |
Skin disorder | 70.19 | 49.28 | 31 | 3123 | 11587 | 29559786 |
Skin discolouration | 67.79 | 49.28 | 33 | 3121 | 15376 | 29555997 |
Musculoskeletal stiffness | 65.82 | 49.28 | 44 | 3110 | 37414 | 29533959 |
Skin hyperpigmentation | 64.00 | 49.28 | 20 | 3134 | 2844 | 29568529 |
Anxiety | 53.37 | 49.28 | 55 | 3099 | 85310 | 29486063 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nephrogenic systemic fibrosis | 3059.04 | 52.38 | 500 | 4191 | 5392 | 64488649 |
Skin hypertrophy | 607.44 | 52.38 | 123 | 4568 | 4406 | 64489635 |
Skin induration | 581.39 | 52.38 | 117 | 4574 | 4058 | 64489983 |
Skin tightness | 520.84 | 52.38 | 110 | 4581 | 4851 | 64489190 |
Skin fibrosis | 314.40 | 52.38 | 59 | 4632 | 1400 | 64492641 |
Joint range of motion decreased | 294.89 | 52.38 | 92 | 4599 | 19251 | 64474790 |
Joint contracture | 263.79 | 52.38 | 55 | 4636 | 2264 | 64491777 |
Fibrosis | 240.12 | 52.38 | 58 | 4633 | 4670 | 64489371 |
Scar | 192.70 | 52.38 | 61 | 4630 | 13337 | 64480704 |
Biopsy brain abnormal | 172.38 | 52.38 | 21 | 4670 | 8 | 64494033 |
Skin hyperpigmentation | 169.51 | 52.38 | 47 | 4644 | 6504 | 64487537 |
Joint stiffness | 143.94 | 52.38 | 61 | 4630 | 30343 | 64463698 |
Oedema peripheral | 135.40 | 52.38 | 116 | 4575 | 210201 | 64283840 |
Mobility decreased | 130.87 | 52.38 | 80 | 4611 | 85760 | 64408281 |
Skin discolouration | 128.93 | 52.38 | 59 | 4632 | 35196 | 64458845 |
Emotional distress | 127.69 | 52.38 | 59 | 4632 | 35979 | 64458062 |
Deformity | 121.71 | 52.38 | 36 | 4655 | 6261 | 64487780 |
Anhedonia | 120.05 | 52.38 | 43 | 4648 | 13663 | 64480378 |
Extremity contracture | 114.42 | 52.38 | 26 | 4665 | 1599 | 64492442 |
Peau d'orange | 102.40 | 52.38 | 18 | 4673 | 291 | 64493750 |
Skin disorder | 100.15 | 52.38 | 46 | 4645 | 27634 | 64466407 |
Pain | 95.65 | 52.38 | 155 | 4536 | 553356 | 63940685 |
Erythema | 84.89 | 52.38 | 85 | 4606 | 186985 | 64307056 |
Muscle contracture | 82.15 | 52.38 | 21 | 4670 | 2124 | 64491917 |
Skin plaque | 81.87 | 52.38 | 29 | 4662 | 8911 | 64485130 |
Injury | 74.69 | 52.38 | 48 | 4643 | 55944 | 64438097 |
Musculoskeletal stiffness | 73.10 | 52.38 | 65 | 4626 | 123141 | 64370900 |
Magnetic resonance imaging head abnormal | 65.57 | 52.38 | 18 | 4673 | 2394 | 64491647 |
Pruritus | 64.19 | 52.38 | 95 | 4596 | 312305 | 64181736 |
Muscle tightness | 61.66 | 52.38 | 25 | 4666 | 11090 | 64482951 |
Skin exfoliation | 61.14 | 52.38 | 39 | 4652 | 44846 | 64449195 |
Anxiety | 58.90 | 52.38 | 73 | 4618 | 202576 | 64291465 |
Pain of skin | 58.25 | 52.38 | 23 | 4668 | 9524 | 64484517 |
Muscular weakness | 57.92 | 52.38 | 58 | 4633 | 127280 | 64366761 |
Magnetic resonance imaging abnormal | 56.62 | 52.38 | 17 | 4674 | 3106 | 64490935 |
Gait disturbance | 56.54 | 52.38 | 66 | 4625 | 172089 | 64321952 |
Dry skin | 54.14 | 52.38 | 38 | 4653 | 51123 | 64442918 |
None
Source | Code | Description |
---|---|---|
ATC | V08CA03 | VARIOUS CONTRAST MEDIA MAGNETIC RESONANCE IMAGING CONTRAST MEDIA Paramagnetic contrast media |
MeSH PA | D003287 | Contrast Media |
MeSH PA | D064907 | Diagnostic Uses of Chemicals |
FDA MoA | N0000175862 | Magnetic Resonance Contrast Activity |
FDA EPC | N0000180184 | Paramagnetic Contrast Agent |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Magnetic resonance imaging | indication | 113091000 |
None
None
None
None
None
None
ID | Source |
---|---|
D04284 | KEGG_DRUG |
4020689 | VUID |
N0000148302 | NUI |
4020689 | VANDF |
CHEBI:31642 | CHEBI |
CHEMBL1200346 | ChEMBL_ID |
C064925 | MESH_SUPPLEMENTAL_RECORD_UI |
6636 | INN_ID |
DB00225 | DRUGBANK_ID |
84F6U3J2R6 | UNII |
60754 | PUBCHEM_CID |
41144 | RXNORM |
10205 | MMSL |
4771 | MMSL |
d04083 | MMSL |
004259 | NDDF |
354088005 | SNOMEDCT_US |
396067007 | SNOMEDCT_US |
C0082646 | UMLSCUI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
OMNISCAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0407-0690 | INJECTION | 287 mg | INTRAVENOUS | NDA | 28 sections |
OMNISCAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0407-0690 | INJECTION | 287 mg | INTRAVENOUS | NDA | 28 sections |
OMNISCAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0407-0690 | INJECTION | 287 mg | INTRAVENOUS | NDA | 28 sections |
OMNISCAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0407-0691 | INJECTION | 287 mg | INTRAVENOUS | NDA | 28 sections |